Cite
HARVARD Citation
Dakhil, S. et al. (n.d.). Phase III safety study of rituximab administered as a 90-minute infusion in patients with previously untreated diffuse large B-cell and follicular lymphoma. Leukemia & lymphoma. 55 (10), pp. 2335-2340. [Online].